Cutaneous dysesthesia / allodynia emerging, dose-related, reversible
A 4-week, randomized, double-blind, placebo-controlled trial showed a significantly improved 24-h blood glucose control [126], and a subsequent pooled post hoc analysis including more than 700 patients provides evidence of the safety and efficacy of a 52 weeks mean follow-up of use of teneligliptin 20 mg daily as monotherapy or in combination with sulfonylurea, glinide, biguanide or -glucosidase inhibitor in Japanese patients with T2DM [127]
as GLP-1 medications stabilize blood glucose levels and reduce glycemic variability, patients frequently experience resolution of these symptoms and perceive increased vitality
Boehringer-Ingelheim (advisory board membership)
Extended-duration safety data will only be available after full clinical trials and regulatory review
However, only four of the seven cancers non-small cell lung cancer, breast cancer, colorectal cancer and liver cancer had a statistically significant reduction in people whose cancer advanced